SEC Form 4
AtriCure, Inc. (ATRC) insider trading
In the 12 months to Nov 16, 2026, 9 ATRC insiders reported open-market sales of $5.1M across 18 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $5.1M
- 18 filings · 9 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 4 of 18
- $1.4M of $5.1M sold (28%)
Who traded ATRC, and when
- Sale
- Sale, pre-arranged (10b5-1)
ATRC daily close from Nov 17, 2025 to Nov 13, 2026, between $25.86 and $65.53, last $56.84. 18 sale and 0 purchase filings by 9 insiders, marked at their filing dates. Salvatore Privitera, Chief Technical Officer: sold $1.4M across 4 filings, first filed Sep 4, 2026, last Nov 5, 2026. Sven Wehrwein, Director: sold $1.3M across 2 filings, first filed Nov 26, 2025, last Jul 30, 2026. Vinayak Doraiswamy, Chief Scientific Officer: sold $523.1K across 3 filings, first filed Mar 16, 2026, last Jul 30, 2026. Karl S. Dahlquist, Chief Legal Officer: sold $458.1K across 1 filing, first filed Aug 26, 2026, last Aug 26, 2026. Justin J. Noznesky, Chief Mktg & Strategy Officer: sold $432.5K across 2 filings, first filed Nov 26, 2025, last Jul 30, 2026. Regina E. Groves, Director: sold $288.1K across 1 filing, first filed Sep 14, 2026, last Sep 14, 2026. 3 others: sold $609.3K across 5 filings, first filed Nov 25, 2025, last Nov 10, 2026.
Largest mark · tap a row for others
Sven Wehrwein · Director
Sale $946,000
25,000 shares at $37.84 avg
Filed Jul 30, 2026 · traded Jul 28
Close on filing date $40.15
Salvatore Privitera · Chief Technical Officer
Chief Technical Officer
$1.4M soldSven Wehrwein · Director
Director
$1.3M soldVinayak Doraiswamy · Chief Scientific Officer
Chief Scientific Officer
$523.1K soldKarl S. Dahlquist · Chief Legal Officer
Chief Legal Officer
$458.1K soldJustin J. Noznesky · Chief Mktg & Strategy Officer
Chief Mktg & Strategy Officer
$432.5K soldRegina E. Groves · Director
Director
$288.1K sold3 others
Combined, one mark per week
$609.3K soldOpen-market trades
18 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Salvatore Privitera | Chief Technical Officer | $1.4M | — | 4 | 100% of sales | |
| Sven Wehrwein | Director | $1.3M | — | 2 | — | |
| Vinayak Doraiswamy | Chief Scientific Officer | $523.1K | — | 3 | — | |
| Karl S. Dahlquist | Chief Legal Officer | $458.1K | — | 1 | — | |
| Justin J. Noznesky | Chief Mktg & Strategy Officer | $432.5K | — | 2 | — | |
| Regina E. Groves | Director | $288.1K | — | 1 | — | |
| Maggie Yuen | Director | $241.6K | — | 2 | — | |
| Karen Prange | Director | $224.2K | — | 2 | — | |
| B. Kristine Johnson | Director | $143.4K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | B. Kristine Johnson Director | Sale | 2,452 | $58.48 | $143.4K | 53,502 | |
traded | Salvatore Privitera Chief Technical Officer | SalePre-arranged (10b5-1) | 8,404 | $65.00 | $546.3K | 134,341 | |
traded | Salvatore Privitera Chief Technical Officer | SalePre-arranged (10b5-1) | 4,519 | $60.00 | $271.1K | 142,745 | |
traded | Regina E. Groves Director | Sale | 5,313 | $54.22 | $288.1K | 34,546 | |
traded | Salvatore Privitera Chief Technical Officer | SalePre-arranged (10b5-1) | 3,657 | $55.00 | $201.1K | 147,264 | |
traded | Salvatore Privitera Chief Technical Officer | SalePre-arranged (10b5-1) | 7,763 | $52.50 | $407.6K | 150,921 | |
traded | Karl S. Dahlquist Chief Legal Officer | Sale | 9,370 | $48.89 | $458.1K | 87,319 | |
traded | Karen Prange Director | Sale | 3,564 | $38.80 | $138.3K | 22,809 | |
traded | Maggie Yuen Director | Sale | 3,500 | $38.42 | $134.5K | 14,015 | |
traded | Sven Wehrwein Director | Sale | 25,000 | $37.84 | $946.0K | 40,518 | |
traded | Justin J. Noznesky Chief Mktg & Strategy Officer | Sale | 6,182 | $38.80 | $239.9K | 100,219 | |
traded | Vinayak Doraiswamy Chief Scientific Officer | Sale | 6,000 | $38.88 | $233.3K | 86,511 | |
traded | Karen Prange Director | Sale | 3,000 | $28.65 | $86.0K | 26,373 | |
traded | Vinayak Doraiswamy Chief Scientific Officer | Sale | 5,000 | $28.13 | $140.7K | 91,875 | |
traded | Vinayak Doraiswamy Chief Scientific Officer | Sale | 5,000 | $29.83 | $149.2K | 96,875 | |
traded | Sven Wehrwein Director | Sale | 10,000 | $37.66 | $376.6K | 34,374 | |
traded | Justin J. Noznesky Chief Mktg & Strategy Officer | Sale | 5,166 | $37.29 | $192.6K | 78,798 | |
traded | Maggie Yuen Director | Sale | 3,000 | $35.72 | $107.2K | 11,371 |
GET /stocks/filings/vX/form-4?tickers=ATRC&filing_date.gte=2025-11-16&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ATRC"
],
"issuer_cik": "0001323885",
"owner_cik": "0001231984",
"accession_number": "0001231984-26-000005",
"form_type": "4",
"filing_date": "2026-11-10",
"period_of_report": "2026-11-06",
"issuer_name": "AtriCure, Inc.",
"issuer_trading_symbol": "ATRC",
"owner_name": "JOHNSON B KRISTINE",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-06",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2452,
"transaction_price_per_share": 58.48,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 53502,
"transaction_value": 143392.96,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction was executed in multiple trades at prices ranging from $58.23 to $58.86 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."
}
]
},
{
"tickers": [
"ATRC"
],
"issuer_cik": "0001323885",
"owner_cik": "0001336063",
"accession_number": "0001336063-26-000012",
"form_type": "4",
"filing_date": "2026-11-05",
"period_of_report": "2026-11-04",
"issuer_name": "AtriCure, Inc.",
"issuer_trading_symbol": "ATRC",
"owner_name": "Privitera Salvatore",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Technical Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-04",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 8404,
"transaction_price_per_share": 65,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 134341,
"transaction_value": 546260,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "These shares were sold pursuant to a 10b5-1 trading plan adopted on February 20, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 45 records
- Option exercises4 records
- Tax withholding7 records
- Grants and awards28 records
- Gifts6 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has AtriCure, Inc.'s CEO sold stock?
No. Michael H. Carrel (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is ATRC’s insider data?
These are ATRC Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ATRC insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ATRC every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.